MA42109A - Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase - Google Patents

Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase

Info

Publication number
MA42109A
MA42109A MA042109A MA42109A MA42109A MA 42109 A MA42109 A MA 42109A MA 042109 A MA042109 A MA 042109A MA 42109 A MA42109 A MA 42109A MA 42109 A MA42109 A MA 42109A
Authority
MA
Morocco
Prior art keywords
kinase inhibitors
heterocyclic amides
amides used
heterocyclic
compounds
Prior art date
Application number
MA042109A
Other languages
English (en)
Other versions
MA42109B1 (fr
Inventor
Niall Andrew Anderson
Deepak Bandyopadhyay
Alain Claude-Marie Daugan
Frederic G Donche
Patrick M Eidam
Nicolas Eric Faucher
Nicolas S George
Philip Anthony Harris
Jae U Jeong
Bryan W King
Clark A Sehon
Gemma Victoria White
David Duff Wisnoski
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of MA42109A publication Critical patent/MA42109A/fr
Publication of MA42109B1 publication Critical patent/MA42109B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Abstract

La présente invention concerne des composés de formule (1) dans laquelle r1, r2, et r3 sont tels que définis dans la description, ainsi que leurs procédés de fabrication et d'utilisation.
MA42109A 2015-05-19 2016-05-19 Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase MA42109B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562163552P 2015-05-19 2015-05-19
US201562167359P 2015-05-28 2015-05-28
US201562197602P 2015-07-28 2015-07-28
PCT/IB2016/052948 WO2016185423A1 (fr) 2015-05-19 2016-05-19 Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase

Publications (2)

Publication Number Publication Date
MA42109A true MA42109A (fr) 2018-03-28
MA42109B1 MA42109B1 (fr) 2021-03-31

Family

ID=56080431

Family Applications (1)

Application Number Title Priority Date Filing Date
MA42109A MA42109B1 (fr) 2015-05-19 2016-05-19 Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase

Country Status (35)

Country Link
US (4) US10590085B2 (fr)
EP (1) EP3298002B1 (fr)
JP (3) JP6700311B2 (fr)
KR (1) KR20180004733A (fr)
CN (2) CN107624111B (fr)
AU (2) AU2016263156B2 (fr)
CA (1) CA2986102C (fr)
CL (1) CL2017002908A1 (fr)
CO (1) CO2017011754A2 (fr)
CR (1) CR20170524A (fr)
CY (1) CY1124187T1 (fr)
DK (1) DK3298002T3 (fr)
DO (1) DOP2017000267A (fr)
EA (1) EA036452B1 (fr)
ES (1) ES2848398T3 (fr)
HR (1) HRP20210300T1 (fr)
HU (1) HUE053564T2 (fr)
IL (1) IL255246A0 (fr)
LT (1) LT3298002T (fr)
MA (1) MA42109B1 (fr)
MX (1) MX383935B (fr)
MY (1) MY192059A (fr)
NZ (1) NZ736665A (fr)
PE (1) PE20180508A1 (fr)
PH (1) PH12017502090A1 (fr)
PL (1) PL3298002T3 (fr)
PT (1) PT3298002T (fr)
RS (1) RS61568B1 (fr)
SG (1) SG11201708707UA (fr)
SI (1) SI3298002T1 (fr)
SM (1) SMT202100101T1 (fr)
TW (1) TWI730959B (fr)
UY (1) UY36680A (fr)
WO (1) WO2016185423A1 (fr)
ZA (1) ZA201707176B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ552543A (en) 2004-06-24 2010-09-30 Vertex Pharma N-( 5-Hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-caboxamide
PL2395002T3 (pl) 2005-11-08 2015-04-30 Vertex Pharma Kompozycja farmaceutyczna zawierająca heterocykliczny modulator transporterów zawierających kasetę wiążącą ATP
PT3219705T (pt) 2005-12-28 2020-05-20 Vertex Pharma Composições farmacêuticas da forma amorfa de n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-di-hidro-4-oxoquinolina-3-carboxamida
CN102863432B (zh) 2007-05-09 2016-09-07 沃泰克斯药物股份有限公司 Cftr调节剂
PL2225230T3 (pl) 2007-12-07 2017-08-31 Vertex Pharmaceuticals Incorporated Stałe postacie kwasu 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-ilo)cyklopropanokarboksyamido)-3-metylopirydyn-2-ylo)benzoesowego
HUE032268T2 (en) 2007-12-07 2017-09-28 Vertex Pharma Process for the preparation of cycloalkylcarboxamidopyridine benzoic acids
EP2271622B1 (fr) 2008-02-28 2017-10-04 Vertex Pharmaceuticals Incorporated Dérivés d'hétéroarènes en tant que modulateurs de CFTR
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
SG10201504084QA (en) 2009-03-20 2015-06-29 Vertex Pharma Process for making modulators of cystic fibrosis transmembrane conductance regulator
EP2555755B2 (fr) 2010-04-07 2019-07-10 Vertex Pharmaceuticals Incorporated Compositions pharmaceutiques de l'acide 3-(6-(1-(2,2-difluorobenzo [d] [1,3] dioxol-5-yle) cyclopropane carboxamido)-3-méthylpyridin-2-yle) benzoïque et leur administration
CN104470518A (zh) 2012-02-27 2015-03-25 沃泰克斯药物股份有限公司 药物组合物及其施用
HRP20210516T2 (hr) 2013-11-12 2021-10-01 Vertex Pharmaceuticals Incorporated Postupak proizvodnje farmaceutskih pripravaka za liječenje bolesti koje su posredovane putem cftr
RS62259B1 (sr) 2014-11-18 2021-09-30 Vertex Pharma Proces izvođenja ispitivanja visoke propusnosti tečne hromatografije visokih performansi
EP3224245B1 (fr) 2014-12-24 2018-09-12 National Institute Of Biological Sciences, Beijing Inhibiteurs de nécrose
UY36680A (es) * 2015-05-19 2016-12-30 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas como inhibidores de quinasa
TW201831464A (zh) * 2016-11-18 2018-09-01 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺
US20200062735A1 (en) 2017-02-27 2020-02-27 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
CN119285572A (zh) 2017-05-17 2025-01-10 戴纳立制药公司 激酶抑制剂及其用途
EP3704097B1 (fr) 2017-10-31 2023-10-25 F. Hoffmann-La Roche AG Sulfones et sulfoxydes bicycliques et procédés d'utilisation associés
WO2019224774A1 (fr) * 2018-05-23 2019-11-28 Glaxosmithkline Intellectual Property Development Limited Amides hétérocycliques en tant qu'inhibiteurs de kinase rip1
WO2019224773A1 (fr) * 2018-05-23 2019-11-28 Glaxosmithkline Intellectual Property Development Limited Amides hétérocycliques en tant qu'inhibiteurs de kinase rip1
WO2020044206A1 (fr) 2018-08-29 2020-03-05 Glaxosmithkline Intellectual Property Development Limited Amides hétérocycliques utiles en tant qu'inhibiteurs de kinases destinés à être utilisés dans le traitement du cancer
AR119673A1 (es) * 2019-01-11 2022-01-05 Hoffmann La Roche Compuestos bicíclicos de cetona y métodos para utilizarlos
CN109912574A (zh) * 2019-05-06 2019-06-21 合肥工业大学 一种二氢吡唑类化合物及其制备方法和用途
US20220235032A1 (en) * 2019-05-09 2022-07-28 Genfleet Therapeutics (Shanghai) Inc. Bisheterocyclic carbonyl substituted dihydropyrazole compound, preparation method therefor and pharmaceutical use thereof
EP3972957A1 (fr) * 2019-05-22 2022-03-30 Agios Pharmaceuticals, Inc. Formes de sel cristallin de n-(4-(4-(cyclopropylméthyl) pipérazine-1-carbonyl)phényl)quinoléine-8-sulfonamide
US11718612B2 (en) 2019-09-06 2023-08-08 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase I for the treatment of disease
IL291665B2 (en) * 2019-09-27 2025-07-01 Univ Texas Inhibitors of receptor interacting protein kinase i for the treatment of disease
AU2020391425A1 (en) 2019-11-26 2022-06-16 Board Of Regents, The University Of Texas System Inhibitors of Receptor Interacting Protein Kinase 1 for the treatment of disease
JP7760530B2 (ja) * 2020-05-20 2025-10-27 シロナックス リミテッド． ピペラジン環状尿素類
US20230192662A1 (en) * 2020-05-20 2023-06-22 Sironax Ltd. Receptor-Interacting Protein 1 Inhibitors Including Piperazine Heterocyclic Amide Ureas
CN115916755A (zh) * 2020-05-20 2023-04-04 维泰瑞隆有限公司 氮杂环丁烷环状脲
TW202214617A (zh) * 2020-06-02 2022-04-16 法商賽諾菲公司 作為ｒｉｐｋ１抑制劑之異㗁唑啶及其用途
CA3218159A1 (fr) * 2021-05-20 2022-11-24 Zhaolan ZHANG Modulateurs de rip1 comprenant des urees cycliques d'azetidine, preparations et utilisations de ceux-ci
EP4643949A2 (fr) 2021-08-10 2025-11-05 AbbVie Inc. Inhibiteurs de nicotinamide ripk1
AU2022388696A1 (en) 2021-11-11 2024-06-27 Genzyme Corporation Isoxazolidines as ripk1 inhibitors and use thereof
JP2025501347A (ja) * 2022-01-04 2025-01-17 北京賽特明強医薬科技有限公司 カルボニル架橋複素環式化合物、ならびにその組成物および用途
US11816144B2 (en) * 2022-03-31 2023-11-14 Pinterest, Inc. Hair pattern determination and filtering
CN115326999B (zh) * 2022-10-12 2022-12-27 深圳市海滨制药有限公司 一种奥司他韦环氧中间体及其异构体的检测方法
WO2024233544A1 (fr) 2023-05-10 2024-11-14 Genzyme Corporation Isoxazolidines en tant qu'inhibiteurs de ripk1 et leur utilisation
WO2024233554A1 (fr) 2023-05-10 2024-11-14 Genzyme Corporation Isoxazolidines en tant qu'inhibiteurs de ripk1 et leur utilisation
WO2024233547A1 (fr) 2023-05-10 2024-11-14 Genzyme Corporation Isoxazolidines en tant qu'inhibiteurs de ripk1 et leur utilisation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH062742B2 (ja) 1987-06-17 1994-01-12 三井東圧化学株式会社 新規２‐ピラゾリン類及びそれを有効成分とする脳血管障害治療剤
HU199825B (en) * 1987-06-17 1990-03-28 Mitsui Toatsu Chemicals Process for production of new derivatives of pirasoline and medical compositions containing them
US4895947A (en) 1987-12-17 1990-01-23 Mitsui Toatsu Chemicals, Inc. Process for producing 1-acyl-2-pyrazoline derivative
CL2004000366A1 (es) 2003-02-26 2005-01-07 Pharmacia Corp Sa Organizada B USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
CA2524274A1 (fr) 2003-05-02 2004-11-18 Elan Pharmaceuticals, Inc. Derives amide 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-acide carboxylique (1-(aminocarbonyl)eth-1-yl) et composes correspondants tels qu e les antagonistes du recepteur de la bradykinine de type b1 pour le traitement des maladies inflammatoires
AR052660A1 (es) 2005-01-21 2007-03-28 Astex Therapeutics Ltd Derivados de pirazol para inhibir la cdk's y gsk's
WO2009086303A2 (fr) 2007-12-21 2009-07-09 University Of Rochester Procédé permettant de modifier la durée de vie d'organismes eucaryotes
AU2009329879A1 (en) 2008-12-23 2011-08-11 President And Fellows Of Harvard College Small molecule inhibitors of necroptosis
BR112013002484B1 (pt) 2010-09-21 2021-10-13 Eisai R&D Management Co. , Ltd. Composto, composição farmacêutica, e, usos de um composto
WO2012125544A2 (fr) * 2011-03-11 2012-09-20 President And Fellows Of Harvard College Inhibiteurs de la nécroptose et leurs méthodes d'utilisation
TWI547494B (zh) * 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
TWI648273B (zh) * 2013-02-15 2019-01-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類（三）
EP3224245B1 (fr) * 2014-12-24 2018-09-12 National Institute Of Biological Sciences, Beijing Inhibiteurs de nécrose
UY36680A (es) 2015-05-19 2016-12-30 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas como inhibidores de quinasa
WO2017096301A1 (fr) 2015-12-04 2017-06-08 Denali Therapeutics Inc. Inhibiteurs dérivés d'isoxazolidine de protéine kinase 1 interagissant avec un récepteur (ripk 1)
TW201831464A (zh) 2016-11-18 2018-09-01 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺
US20200062735A1 (en) 2017-02-27 2020-02-27 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors

Also Published As

Publication number Publication date
WO2016185423A1 (fr) 2016-11-24
AU2016263156B2 (en) 2018-12-06
JP7204821B2 (ja) 2023-01-16
MX383935B (es) 2025-03-14
EA036452B1 (ru) 2020-11-12
MA42109B1 (fr) 2021-03-31
CA2986102A1 (fr) 2016-11-24
US20210253532A1 (en) 2021-08-19
AU2019201480B2 (en) 2020-06-11
PT3298002T (pt) 2020-12-28
ZA201707176B (en) 2019-05-29
AU2016263156A1 (en) 2017-11-16
US20200165205A1 (en) 2020-05-28
TWI730959B (zh) 2021-06-21
PE20180508A1 (es) 2018-03-09
SMT202100101T1 (it) 2021-03-15
PL3298002T3 (pl) 2021-06-14
CL2017002908A1 (es) 2018-04-20
EA201792535A1 (ru) 2018-10-31
CO2017011754A2 (es) 2018-02-09
US20230120185A1 (en) 2023-04-20
JP2020143079A (ja) 2020-09-10
US10899716B2 (en) 2021-01-26
HUE053564T2 (hu) 2021-07-28
MX2017014809A (es) 2018-02-09
DOP2017000267A (es) 2018-01-31
JP6700311B2 (ja) 2020-05-27
PH12017502090A1 (en) 2018-05-07
MY192059A (en) 2022-07-25
HRP20210300T1 (hr) 2021-04-02
CN112370452A (zh) 2021-02-19
CR20170524A (es) 2018-01-22
DK3298002T3 (da) 2021-02-15
KR20180004733A (ko) 2018-01-12
RS61568B1 (sr) 2021-04-29
HK1245244A1 (en) 2018-08-24
CY1124187T1 (el) 2022-05-27
CN107624111B (zh) 2020-11-03
EP3298002A1 (fr) 2018-03-28
US20180134665A1 (en) 2018-05-17
ES2848398T3 (es) 2021-08-09
US11485710B2 (en) 2022-11-01
US10590085B2 (en) 2020-03-17
AU2019201480A1 (en) 2019-03-28
IL255246A0 (en) 2017-12-31
TW201718508A (zh) 2017-06-01
UY36680A (es) 2016-12-30
JP2021138731A (ja) 2021-09-16
EP3298002B1 (fr) 2020-12-16
LT3298002T (lt) 2021-01-11
NZ736665A (en) 2024-10-25
CA2986102C (fr) 2024-01-02
CN107624111A (zh) 2018-01-23
SI3298002T1 (sl) 2021-04-30
AU2019201480C1 (en) 2021-11-25
JP6893271B2 (ja) 2021-06-23
BR112017024941A2 (pt) 2018-07-31
JP2018515555A (ja) 2018-06-14
SG11201708707UA (en) 2017-12-28

Similar Documents

Publication Publication Date Title
MA42109A (fr) Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase
MA44820A1 (fr) Amides hétérocycliques a utiliser en tant qu'inhibiteurs de kinase
EA201991697A1 (ru) Сульфоксиминовые ингибиторы гликозидазы
EA201790271A1 (ru) Ингибиторы гликозидазы
EA201991198A1 (ru) АМИНОТИАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ c-Kit
MA35434B1 (fr) Amino-quinazolines en tant qu'inhibiteurs de kinase
MA39193A1 (fr) Modulateurs du gpr6 à base de tétrahydropyridopyrazines
EA201991197A1 (ru) БЕНЗИМИДАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ c-Kit
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
MA39152B1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
EA201892147A1 (ru) Бициклические соединения
MA39211B1 (fr) Composés tricycliques comme agents anti-cancers
JO3515B1 (ar) مثبطات fgfr4 بيريميدين
MX2018010191A (es) Inhibidores de glucosidasa.
CR20180541A (es) Inhibidores de bromodominios
MA40281B1 (fr) Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t
MA38884A1 (fr) Composé de triazolopyridine, compositions et procédés d'utilisation associés
MA39170A1 (fr) Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer
JO3261B1 (ar) مشتق بيريدين أحادي الحلقة
BR112013004624A2 (pt) "derivados de furopiridina"
EA201790206A1 (ru) Новые 2,5-замещенные пиримидины в качестве ингибиторов pde4
MA39171A1 (fr) Dérivés d'hydroxy formamide et leur utilisation
MY195889A (en) Phenyl Derivatives as Cannabinoid Receptor 2 Agonists
MA40366A (fr) Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines
MA41337A (fr) Dérivés de l'hydroxyalkyl pipérazine utilisés comme modulateurs du récepteur cxcr3